Human herpesvirus 8-associated neoplasms: The roles of viral replication and antiviral treatment

Current Opinion in Infectious Diseases

Volumn 24, Issue 4, 2011, Pages 295-301

  Gantt, Soren ^a,c   Casper, Corey ^a,b,d  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

antiviral; human herpesvirus 8; Kaposi sarcoma; replication

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; VALACICLOVIR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; CANCER CELL; CLINICAL TRIAL; DNA SYNTHESIS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KAPOSI SARCOMA; LYTIC REPLICATION; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; REVIEW; TREATMENT OUTCOME; VIRUS GENE; VIRUS REPLICATION;

GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; SARCOMA, KAPOSI;

EID: 79960275404     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283486d04     Document Type: Review

References (90)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Parkin DM, Ferlay J, Hamdi-Ché rif M, et al.International Agency for Research on Cancer. Cancer in Africa: epidemiology and prevention. IARC scientific publications. Lyon, France: IARC Press; 2003. pp. 1-414.
3. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120:939-949.
4. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010; 289:140-150.
5. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10:707-719.
6. Ciufo DM, Cannon JS, Poole LJ, et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol 2001; 75:5614-5626. (Pubitemid 32488155)
7. Tang J, Gordon GM, Muller MG, et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J Virol 2003; 77: 5975-5984. (Pubitemid 36538988)
8. Gao SJ, Deng JH, Zhou FC. Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol 2003; 77:9738-9749.
9. Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol 2006; 80:7179-7185. (Pubitemid 44025214)
10. Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997; 71:715-719. (Pubitemid 26412345)
11. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156:743-749. (Pubitemid 30626930)
12. Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269:335-344. (Pubitemid 30210906)
13. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113:124-136. (Pubitemid 38541639)
14. Flamand L, Zeman RA, Bryant JL, et al. Absence of human herpesvirus 8 DNA sequences in neoplastic Kaposi's sarcoma cell lines. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:194-197. (Pubitemid 26341873)
15. Dictor M, Rambech E, Way D, et al. Human herpesvirus 8 (Kaposi's sarcomaassociated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients. Am J Pathol 1996; 148:2009-2016.
16. Aluigi MG, Albini A, Carlone S, et al. KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi's sarcoma. Res Virol 1996; 147:267-275. (Pubitemid 26276045)
17. Asahi-Ozaki Y, Sato Y, Kanno T, et al. Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases. J Infect Dis 2006; 193:773-782.
18. Parravinci C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151:1517-1522. (Pubitemid 27527913)
19. Broccolo F, Bossolasco S, Careddu AM, et al. Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 2002; 9:1222-1228. (Pubitemid 35283283)
20. Cannon MJ, Dollard SC, Black JB, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-222. (Pubitemid 36183048)
21. Lin L, Lee JY, Kaplan LD, et al. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 2009; 27:2496-2502.
22. Johnston C, Orem J, Okuku F, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One 2009; 4:e4222.
23. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109-2116.
24. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799-802.
25. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847-1851. (Pubitemid 37000104)
26. Campbell TB, Staskus KA, Folkvord J, et al. Persistence of Kaposi sarcomaassociated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases. J Infect Dis 2005; 191:367-371. (Pubitemid 40139761)
27. Lorenzen T, Albrecht D, Paech V, et al. HHV-8 DNA in blood and the development of HIV-associated Kaposi's sarcoma in the era of HAART: a prospective evaluation. Eur J Med Res 2002; 7:283-286.
28. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma: associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390. (Pubitemid 35397090)
29. Jones JL, Hanson DL, Chu SY, et al. AIDS-associated Kaposi's sarcoma. Science 1995; 267:1078-1079.
30. Mocroft A, Youle M, Gazzard B, et al. Antiherpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101-1105. (Pubitemid 26283347)
31. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173:1477-1480. (Pubitemid 26286811)
32. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491-1497. (Pubitemid 26166891)
33. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063-1070. (Pubitemid 29162510)
34. Engels EA, Whitby D, Goebel PB, et al. Identifying human herpesvirus 8 infection: performance characteristics of serologic assays. J Acquir Immune Defic Syndr 2000; 23:346-354. (Pubitemid 30327038)
35. Sarmati L. Serological testing for human herpesvirus 8. Herpes 2001; 8:76-79.
36. Carbone A, Cesarman E, Gloghini A, Drexler HG. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS 2010; 24:479-490.
37. Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.AmJ Transplant 2009; 9 (Suppl 4): S87-S96.
38. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-795.
39. Pellet C, Chevret S, Blum L, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863. (Pubitemid 33001202)
40. El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008; 22:1019-1028. (Pubitemid 351769740)
41. Borok M, Fiorillo S, Gudza I, et al. Evaluation of plasma human herpesvirus DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342-349.
42. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 1997; 175:1198-1201.
43. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 2000; 96:2069-2073.
44. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-1634. (Pubitemid 38268952)
45. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41:2754-2756. (Pubitemid 27524753)
46. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11:1327-1332. (Pubitemid 27423292)
47. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082-2086. (Pubitemid 27203763)
48. Friedrichs C, Neyts J, Gaspar G, et al. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 2004; 62:121-123. (Pubitemid 38569940)
49. Zhu W, Burnette A, Dorjsuren D, et al. Potent antiviral activity of northmethanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother 2005; 49:4965-4973. (Pubitemid 41778907)
50. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30. (Pubitemid 351920285)
51. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 2003; 187:149-153. (Pubitemid 36034485)
52. Gantt S, Carlsson J, Ikoma M, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011 [Epub ahead of print]. This is the first demonstration that an antiretroviral drug, nelfinavir, can inhibit HHV-
53. Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the antitumor activity of an immunosuppressant drug. PLoS One 2011, 6:e14535.
54. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renaltransplant recipients. N Engl J Med 2005; 352:1317-1323. (Pubitemid 40411498)
55. Fife K, Gill J, Bourboulia D, et al. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br J Dermatol 1999; 141:1148-1149.
56. Mazzi R, Parisi SG, Sarmati L, et al. Efficacy of cidofovir on human herpesvirus viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 2001; 15:2061-2062. (Pubitemid 32980655)
57. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26:749-752.
58. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:34-38. (Pubitemid 29045467)
59. Lu M, Suen J, Frias C, et al. Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol 2004; 78:13637-13652. (Pubitemid 39612763)
60. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005; 105:4028-4034. (Pubitemid 40656152)
61. Shaw RN, Arbiser JL, Offermann MK. Valproic acid induces human herpesvirus lytic gene expression in BCBL-1 cells. Aids 2000; 14:899-902. (Pubitemid 30303472)
62. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17:447-455. (Pubitemid 41224925)
63. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006; 20:1567-1569. (Pubitemid 44100226)
64. Low P, Neipel F, Rascu A, et al. Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. Eur J Med Res 1998; 3:461-464.
65. Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirusrelated primary effusion lymphoma. Br J Haematol 2000; 111:1112-1115. (Pubitemid 32104925)
66. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15:280-282. (Pubitemid 32142309)
67. Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002; 74:131-132.
68. Stingaciu S, Ticchioni M, Sudaka I, et al. Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient. Clin Adv Hematol Oncol 2010, 8:367-374.
69. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-4369; author reply 4369. (Pubitemid 38685387)
70. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-1210. (Pubitemid 34993870)
71. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDSassociated Kaposi's sarcoma. Clin Microbiol Rev 2002; 15:310-326. (Pubitemid 34303768)
72. Aoki Y, Tosato G. Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol 2007; 312:309-326. (Pubitemid 47400342)
73. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22. (Pubitemid 36951678)
74. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000-1006.
75. Grabar S, Abraham B, Mahamat A, et al. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24:3408-3414. (Pubitemid 46638897)
76. Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009; 51:305-309.
77. Bani-Sadr F, Fournier S, Molina JM. Relapse of Kaposi's sarcoma in HIVinfected patients switching from a protease inhibitor to a nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 2003; 17:1580-1581. (Pubitemid 36900568)
78. Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials 2003; 4:107-114. (Pubitemid 36410914)
79. Rey D, Schmitt MP, Partisani M, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001; 27:459-462. (Pubitemid 32801074)
80. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009; 10:61-71.
81. Monini P, Sgadari C, Toschi E, et al. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4:861-875. (Pubitemid 39472953)
82. Bais C, Van Geelen A, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003; 3:131-143. (Pubitemid 37443386)
83. Morris VA, Punjabi AS, Lagunoff M. Activation of Akt through gp130 receptor signaling is required for Kaposi's sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells. J Virol 2008; 82:8771-8779.
84. Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109:2165-2173. (Pubitemid 46348219)
85. Wu W, Zhang R, Salahub DR. Nelfinavir: a magic bullet to annihilate cancer cells? Cancer Biol Ther 2009; 8:233-235.
86. Gustafson EA, Schinazi RF, Fingeroth JD. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 2000; 74:684-692. (Pubitemid 30036204)
87. Lock MJ, Thorley N, Teo J, Emery VC. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 2002; 49:359-366. (Pubitemid 34162629)
88. Casper C. The increasing burden of HIV-associated malignancies in resourcelimited regions. Annu Rev Med 2011, 62:157-170.
89. Martellotta F, Berretta M, Vaccher E, et al. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7:634-638.
90. Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009; 23:534-538.